LAUNXP Biomedical Co., Ltd (6876.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$13.90 (-1.07%) as of
Key statistics
- Market cap
- 980.35M
- EPS (TTM)
- -7.83
- Dividend yield
- 0.00%
- 52-week range
- 9.09 – 25.45
- Profit margin
- 0.00%
- Volume
- 89.75k
About LAUNXP Biomedical Co., Ltd
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taichung, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.